Clinical DevelopmentLast reviewed April 2026

Decentralized Clinical Trial(DCT)

A clinical trial where some or all trial activities take place at locations other than traditional research sites, often including patient homes.

Usage Examples

The Phase 3 hybrid DCT combined in-person site visits for pivotal endpoints with remote eConsent and home-delivered investigational product.
Wearable-based continuous monitoring replaced weekly in-clinic vital signs assessments.

What is DCT?

Decentralized Clinical Trials (DCTs) use technologies and services to enable trial activities at locations convenient to participants — home visits, telehealth consultations, remote consent, shipped investigational product, wearable monitoring — rather than requiring all visits at traditional research sites. DCT elements can range from fully decentralized (no site visits) to hybrid (mixing remote and in-person activities).

FDA's 2024 final guidance on DCTs addresses regulatory expectations: informed consent adequacy, remote data collection integrity, investigational product accountability at patient homes, safety monitoring adequacy, and investigator oversight of decentralized activities. DCTs can improve access for underrepresented populations and reduce participant burden but require rigorous operational planning, technology validation, and risk-based site oversight.

Regulatory Context

This term appears most often in clinical development workflows where submission quality, regulatory evidence, and audit readiness depend on consistent language. It is commonly referenced alongside 21 CFR 312, ICH E6, FDA DCT GUIDANCE 2024.

FDAEMAPMDA

When This Matters

The Phase 3 hybrid DCT combined in-person site visits for pivotal endpoints with remote eConsent and home-delivered investigational product.
Wearable-based continuous monitoring replaced weekly in-clinic vital signs assessments.

Common Mistakes

Applying one-region clinical assumptions to global submission strategies.
Missing protocol-to-regulation traceability for pivotal studies.
Underestimating how regional guidance updates impact trial documentation.

Related Regulations

21 CFR 312ICH E6FDA DCT GUIDANCE 2024

Frequently Asked Questions

Not necessarily. Most DCTs are hybrid — combining remote and traditional site activities. Full decentralization (no site visits) is possible for some endpoints and indications but remains uncommon. Regulatory acceptance depends on endpoint measurability and safety assurance.

Yes, with appropriate design. FDA's 2024 guidance explicitly acknowledges DCT applicability for pivotal trials. Sponsor and FDA should discuss DCT design during pre-IND or pre-submission meetings to confirm adequacy for the intended approval package.

Investigator oversight of decentralized activities. The trial investigator remains responsible for participant safety and data integrity under 21 CFR 312.60. Structures for remote monitoring, documentation, and escalation must be robust enough to support that responsibility at distance.